Akari Therapeutics
AKTX
11 hedge funds and large institutions have $37M invested in Akari Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 4 closing their positions.
34% more capital invested
Capital invested by funds: $27.5M → $37M (+$9.43M)
0% less ownership
Funds ownership: 0% → 0% (-0%)
27% less funds holding
Funds holding: 15 → 11 (-4)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$5.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.39M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$714K |
| 3 |
QF
QVT Financial
New York
|
-$347K |
| 4 |
BC
Boxer Capital
San Diego,
California
|
-$314K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$120K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DM
1
Deerfield Management
New York
| $12.7M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $5.84M | – | – | – |
|
|
BBA
3
Baker Bros. Advisors
New York
| $5.5M | – | – | – |
|
|
NMC
4
NEA Management Company
Timonium,
Maryland
| $5M | – | – | – |
|
|
VMI
5
VHCP Management II
New York
| $4.09M | – | – | – |
|
|
QF
6
QVT Financial
New York
| $1.89M | -$347K | -62 | -19% |
|
|
BC
7
Boxer Capital
San Diego,
California
| $1.05M | -$314K | -56 | -32% |
|
|
GTC
8
Ghost Tree Capital
New York
| $516K | – | – | – |
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $258K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $50K | -$118K | -21 | -78% |
|
|
11
Wells Fargo
San Francisco,
California
| $7K | +$5.6K | +1 | New |
|
12
Morgan Stanley
New York
| $3K | – | – | – |
|
|
FCMI
13
Foresite Capital Management III
Larkspur,
California
| – | -$1.39M | -246 | Closed |
|
|
RCM
14
RA Capital Management
Boston,
Massachusetts
| – | -$714K | -127 | Closed |
|
|
SM
15
Sabby Management
Miami Beach,
Florida
| – | -$120K | -22 | Closed |
|
16
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$4K | -1 | Closed |
|
AKTX Hedge Fund Activity: Q1 2017 in Review
11 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2017, worth a combined $37M — up 34% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AKTX and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Wells Fargo, opening a new position worth an estimated $5.6K. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $1.39M sold.
- 11 institutional investors held Akari Therapeutics (AKTX) as of Q1 2017, down from 15 in Q4 2016.
- Funds reported $37M of Akari Therapeutics stock for Q1 2017, up 34% quarter-over-quarter.
- 1 fund opened new Akari Therapeutics positions in Q1 2017 and 4 closed out, a net change of -3 holders.
- The largest Akari Therapeutics buyer in Q1 2017 was Wells Fargo, an estimated $5.6K added.
- The largest Akari Therapeutics seller in Q1 2017 was Foresite Capital Management III, an estimated $1.39M sold.
Based on aggregated 13F filings for Q1 2017.